Last reviewed · How we verify
F182112
At a glance
| Generic name | F182112 |
|---|---|
| Sponsor | Shandong New Time Pharmaceutical Co., LTD |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma (PHASE2)
- Phase 1 Study of F182112 in Patients With Relapsed or Refractory Multiple Myeloma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- F182112 CI brief — competitive landscape report
- F182112 updates RSS · CI watch RSS
- Shandong New Time Pharmaceutical Co., LTD portfolio CI